2026-01-18 - Analysis Report
**Financial Report: Thermo Fisher Scientific Inc (TMO)**

**Company Overview:** Leader in life sciences and laboratory research equipment.

**Return Rate Comparison:**

- Cumulative return of review stock: **41.38%**
- Cumulative return of comparison stock (S&P 500, VOO): **93.36%**
- Divergence: **-50.80**, relative divergence: **15.10%**

**Alpha, Beta Analysis:**

| Year      | CAGR | MDD  | Alpha | Beta | Cap(B) |
|-----------|------|------|-------|------|-------|
| 2016-2018 | 21.0%| 17.1%| 17.0% | 1.1  | 84.1B |
| 2017-2019 | 46.0%| 17.1%| 29.0% | 1.1  | 122.1B |
| 2018-2020 | 22.0%| 17.1%| 1.0% | 0.8  | 175.0B |
| 2019-2021 | 77.0%| 15.0%| 34.0% | 0.8  | 250.7B |
| 2020-2022 | 8.0% | 25.4%| 10.0% | 0.8  | 206.9B |
| 2021-2023 | -30.0%| 28.6%| -31.0%| 0.9  | 199.4B |
| 2022-2024 | -37.0%| 24.4%| -57.0%| 0.9  | 195.4B |
| 2023-2025 | -17.0%| 27.2%| -79.0%| 0.8  | 217.7B |

**Recent Stock Price Fluctuations:**

### Stock Price Indicators

*   Close:    **$618.72**
*   Last-market: **-0.95%** from previous Close
*   5-day SMA: **$617.55**
*   20-day SMA: **$597.42**
*   60-day SMA: **$581.89**

### Analysis

Current stock price is fluctuating as indicated by the negative change percentage. However, the 5-day, 20-day and 60-day moving average prices are lower than the current stock price, hinting at possible price drop due to market fluctuation.

**RSI and PPO Index Indicators:**

### Market Indicators

-   Market Risk Indicator (MRI): **0.80**, medium investment risk level
-   RSI: **66.79**
-   PPO: **0.30**
-   Recent (20 days) relative divergence change: **2.50** (+), improving
-   7-day Rank change: **0**,  flat
-   7-day Dynamic Expected Return change: **0.00**, flat

### Analysis

The relatively medium-risk investment level is shown in the Market Risk Indicator (MRI). Meanwhile, the RSI at 66.79 can be categorize in a moderate value. The value of PPO can imply market decline. Additionally, other market indicators reveal that the improvement in market relative divergence within the last 20 days.

**Expected Return**: **-41.00%** (expected excess return compared to S&P 500 if invested long-term)

**News & Significant Events:**

*   [2026-01-17] Thermo Fisher Scientific (TMO) Valuation After Leadership Shakeup And New AI Lab Partnerships - simplywall.st
*   [2026-01-06] Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
*   [2026-01-15] Thermo Fisher Scientific Inc. $TMO Stock Position Raised by MGO One Seven LLC - MarketBeat
*   [2026-01-06] Here's How Much You'd Have If You Invested $1000 in Thermo Fisher Scientific a Decade Ago - Nasdaq
*   [2026-01-14] Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now? - TradingView
*   [2026-01-12] How Thermo Fisher and NVIDIA want to turn routine labs into AI powerhouses - Stock Titan

### Analysis

Multiple news articles are mentioning the recent leadership shakeup and the new AI lab partnerships. The overall sentiment is positive with some mentioning potential for growth and others advising caution.

**Analyst Opinions:**

- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
  - Opinions: 23
  - Target Price (avg/high/low): 651.52 / 750.00 / 575.00

### Analysis

Analysts have a consensus of buying with a mean opinion of slightly towards Buy category. However, opinions vary across analysts. This suggests that there are mixed opinions about the stock. The average, high and low target prices for the stock are $651.52, $750.00, and $575.00 respectively.

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|----|----:|-------:|
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |

### Analysis

The recent earnings per share (EPS) for 2025 are higher than previous quarters. The revenue for 2025 Q3 is significantly higher than other quarters.

**Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

### Analysis

In 2025 Q3 and Q4, Thermo Fisher Scientific has shown a higher profit margin compared to previous quarters. However, the revenue for 2024 Q4 is significantly lower than its Q2.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

### Analysis

The company's equity in 2025 is increasing steadily. Return on Equity (ROE) is decreasing across quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.